This report covers the 7 major markets and provides an Excel-based forecast model for the Metabolic Dysfunction-Associated Steatohepatitis (MASH) market through 2032.
The analyst estimated that drug sales for MASH in 2022 were approximately $802.3 million across the 7MM, with the market size anticipated to grow to approximately $20.3 billion by 2032, at a compound annual growth rate (CAGR) of 38.2%.
Major drivers of growth during the forecast period include the anticipated launch of several pipeline agents including those within the GLP-1RA drug class such as Novo Nordisk’s semaglutide, an increase in the prevalence of MASH, and anticipated increase in use of non-invasive tests for diagnosing and managing MASH.
Despite the recent FDA approval of Madrigal Pharmaceuticals’ Rezdiffra as the first-to-market therapy for MASH, several unmet needs remain within this disease space, with the most substantial need centered on availability of more approved therapies for the disease.
The analyst estimated that drug sales for MASH in 2022 were approximately $802.3 million across the 7MM, with the market size anticipated to grow to approximately $20.3 billion by 2032, at a compound annual growth rate (CAGR) of 38.2%.
Major drivers of growth during the forecast period include the anticipated launch of several pipeline agents including those within the GLP-1RA drug class such as Novo Nordisk’s semaglutide, an increase in the prevalence of MASH, and anticipated increase in use of non-invasive tests for diagnosing and managing MASH.
Despite the recent FDA approval of Madrigal Pharmaceuticals’ Rezdiffra as the first-to-market therapy for MASH, several unmet needs remain within this disease space, with the most substantial need centered on availability of more approved therapies for the disease.
Scope
- Overview of Metabolic Dysfunction-Associated Steatohepatitis (MASH), including epidemiology, symptoms, diagnosis, and disease management.
- Annualized MASH therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the MASH therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MASH treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global MASH therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM MASH therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM MASH therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 MASH: Executive Summary
2 Introduction
3 Disease Overview
4 Epidemiology
5 Disease Management
6 Competitive Assessment
7 Unmet Needs and Opportunity Assessment
8 R&D Strategies
9 Pipeline Assessment
10 Pipeline Valuation Analysis
11 Current and Future Players
12 Market Outlook
13 Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Kowa Co Ltd
- GSK plc
- Eli Lilly and Co
- Ionis Pharmaceuticals Inc
- Hanmi Pharmaceuticals Co Ltd
- Alnylam Pharmaceuticals Inc
- Sagimet Biosciences Inc
- Altimmune Inc
- Madrigal Pharmaceuticals Inc
- Corcept Therapeutics Inc
- BioVie Inc
- Gilead Sciences
- Zydus Lifesciences Ltd
- Boehringer Ingelheim
- Galectin Therapeutics Inc
- Poxel SA
- Viking Therapeutics Inc
- Boston Pharmaceuticals Inc
- NorthSea Therapeutics BV
- Akero Therapeutics Inc
- D&D Pharmatech Co Ltd
- 89bio Inc
- HighTide Therapeutics Inc
- Rivus Pharmaceuticals Inc
- Regeneron GmbH
